HPV Vaccines

U.S. Cancer Rates Fall Overall, but Some HPV-associated Cancers Rise

Deaths due to all types of cancer combined decreased for men and women of all racial/ethnic groups in the U.S., according to a joint "Annual Report to the Nation," published in the January 7, 2013, advance edition of the Journal of the National Cancer Institute. Incidence of oral and anal cancer increased, however, leading the report authors to call for wider use of human papillomavirus (HPV) vaccines.

alt

Read more:

HPV Vaccine Reduces Cervical Abnormalities

Vaccination of young women in Australia against human papillomavirus (HPV) lowered incidence of serious cervical cell abnormalities and early cervical cancer by nearly 40%. alt

Read more:

Gardasil HPV Vaccine Approved for Anal Cancer

On December 22, 2010, the U.S. Food and Drug Administration (FDA) approved the use of Merck's quadrivalent human papillomavirus (HPV) vaccine, Gardasil, for prevention of anal cancer in men and women age 9-26 years. The vaccine -- which targets high-risk HPV types 6, 11, 16, and 18 -- was previously approved for prevention of cervical cancer in young women.

Read more: